Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
CCR5 monoclonal antibodies for HIV-1 therapy
Current opinion in HIV & AIDS, v 4(2), pp 104-111
01 Mar 2009
PMID: 19339948
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Purpose of review
To summarize emerging clinical and preclinical data pertaining to the use of CCR5 monoclonal antibodies (mAbs) as therapies for HIV-1 infection. The epitope specificity of CCR5 mAbs is discussed in relation to its critical impact on antiviral activity and CCR5 antagonism. We compare and contrast mAbs and small-molecule CCR5 antagonists in terms of their binding and antiviral properties. Two CCR5 mAbs have entered clinical testing and have successfully completed proof-of-concept studies in HIV-infected individuals, providing initial information on the potential therapeutic utility of these agents.
Recent findings
New studies support the view that the most potent antiviral CCR5 mAbs recognize the second extracellular loop of CCR5 either exclusively or in combination with the amino terminus. Studies have revealed fundamental differences in how mAbs and small molecules bind CCR5 and inhibit HIV-1. CCR5 mAbs and small-molecule CCR5 antagonists have demonstrated consistent antiviral synergy and limited or no viral cross-resistance in independent studies. Single intravenous infusions of CCR5 mAbs significantly reduced HIV-1 RNA levels in infected individuals for 2-3 weeks without appreciable toxicity.
Summary
CCR5 mAbs have demonstrated broad and potent antiviral activity in vitro. Clinical studies have established CCR5 mAbs as potent antiretroviral agents with prolonged activity following a single dose. CCR5 mAbs represent both a distinct class of CCR5 inhibitor and a novel approach to HIV-1 therapy.
Metrics
Details
- Title
- CCR5 monoclonal antibodies for HIV-1 therapy
- Creators
- William C. Olson - Progenics Pharmaceuticals (United States)Jeffrey M. Jacobson - Drexel University
- Publication Details
- Current opinion in HIV & AIDS, v 4(2), pp 104-111
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 8
- Grant note
- U19AI066329 / NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID) AI066329 / Public Health Service from National Institute of Allergy and Infectious Diseases; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)
- Resource Type
- Journal article
- Language
- English
- Web of Science ID
- WOS:000208083000005
- Scopus ID
- 2-s2.0-65549100122
- Other Identifier
- 991019335515504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Industry collaboration
- Domestic collaboration
- Web of Science research areas
- Immunology
- Infectious Diseases